By Ben Butkus

Gen-Probe this week reported record revenues of $158.2 million in the fourth quarter of 2011, driven primarily by sales of clinical diagnostics and blood screening products.

The positive performance was primarily fueled by domestic and international growth of its Aptima Combo 2 assay for chlamydia and gonorrhea; and by increased shipments of assays and Tigris instruments to blood-screening partner Novartis, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.